CD14 and metabolic disease: The minor CD16+ Mo subpopulation comprises the remaining 10–15% and is subdivided further into intermediate monocytes (IM; CD14+CD16+) and non-classical monocytes (NCM; CD14-CD16++), both with a pro-inflammatory phenotype and are elevated in chronic inflammatory and metabolic diseases [12–18].